Tuberculosis and its association with CD4 T cell count among adult HIV positive patients in Ethiopian settings: a systematic review and meta-analysis.

Background: Tuberculosis (TB) and HV have been intertwined and makeup a deadly human syndemic worldwide, especially in developing countries like Ethiopia. Previous studies have reported different TB incidences and its association with CD4 T cell counts among HIV positive patients in Ethiopia. Thus, the goal of this meta-analysis was, first, to determine pooled incident TB among adult HIV positive patients, and second, to assess the association between incident TB and baseline CD4 T cell count strata's.

Methods: We searched PubMed, Cochrane library, Science Direct and Google scholar databases from June 1 to 30, 2018. The I statistics and Egger's regression test was used to determine heterogeneity and publication bias among included studies respectively. A random effects model was used to estimate pooled incident TB and odds ratio with the respective 95% confidence intervals using Stata version 11.0 statistical software.

Results: A total of 403 research articles were identified, and 10 studies were included in the meta-analysis. The pooled incident TB among adult HIV infected patients in Ethiopia was 16.58% (95% CI; 13.25-19.91%). Specifically, TB incidence in Pre-ART and ART was 17.16% (95% CI; 7.95-26.37%) and 16.24% (95% CI; 12.63-19.84%) respectively. Moreover, incident TB among ART receiving patients with baseline CD4 T cell count < and > 200 cells/mm was 28.86% (95% CI; 18.73-38.98%) and 13.7% (95% CI; 1.41-25.98%) correspondingly. The odds of getting incident TB was 2.88 (95% CI; 1.55-5.35%) for patients with baseline CD4 T cell count < 200 cells/mm compared to patients with baseline CD4 T cell count > 200 cells/mm.

Conclusion: High incident TB among adult HIV positive patients was estimated, especially in patients with CD4 T cell count < 200 cells/mm. Therefore, Early HIV screening and ART initiation, as well as strict compliance with ART and increasing the coverage of TB preventive therapy to more risky groups are important to prevent the problem.

Trial Registration: Study protocol registration: CRD42018090802.